Skip to main content
Terug
INCY logo

Incyte Corporation

Datakwaliteit: 100%
INCY
NASDAQ Healthcare Biotechnology
€ 90,62
▲ € 0,17 (0,19%)
Marktkapitalisatie: 18,03B
Dagbereik
€ 89,25 € 91,70
52-Weeksbereik
€ 53,56 € 112,29
Volume
1.584.227
50D / 200D Gem.
€ 100,52 / € 89,67
Vorige Slotkoers
€ 90,45

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 14,0 0,3
P/B 3,5 2,9
ROE % 29,9 3,7
Net Margin % 25,0 3,8
Rev Growth 5Y % 14,6 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 108,90 +20.2%
Low: € 84,00 High: € 135,00
Forward K/W
12,1
Forward WPA
€ 7,50
WPA Groei (sch.)
+0,0%
Omzet Sch.
5,6 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,03
€ 3,79 – € 4,69
 4,7 B 4
FY2029 € 3,52
€ 3,31 – € 4,09
 4,6 B 4
FY2028 € 9,60
€ 6,20 – € 12,73
 6,5 B 11

Belangrijkste Punten

Revenue grew 14,55% annually over 5 years — strong growth
Earnings grew 3844,96% over the past year
ROE of 29,87% indicates high profitability
Net margin of 25,03% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 1,35B in free cash flow

Groei

Revenue Growth (5Y)
14,55%
Revenue (1Y)21,22%
Earnings (1Y)3844,96%
FCF Growth (3Y)73,69%

Kwaliteit

Return on Equity
29,87%
ROIC19,23%
Net Margin25,03%
Op. Margin26,12%

Veiligheid

Debt / Equity
0,01
Current Ratio3,32
Interest Coverage553,03

Waardering

P/E Ratio
14,02
P/B Ratio3,49
EV/EBITDA11,18
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,22% Revenue Growth (3Y) 17,95%
Earnings Growth (1Y) 3844,96% Earnings Growth (3Y) 46,73%
Revenue Growth (5Y) 14,55% Earnings Growth (5Y) 7,92%
Profitability
Revenue (TTM) 5,14B Net Income (TTM) 1,29B
ROE 29,87% ROA 18,49%
Gross Margin 91,47% Operating Margin 26,12%
Net Margin 25,03% Free Cash Flow (TTM) 1,35B
ROIC 19,23% FCF Growth (3Y) 73,69%
Safety
Debt / Equity 0,01 Current Ratio 3,32
Interest Coverage 553,03 Dividend Yield 0,00%
Valuation
P/E Ratio 14,02 P/B Ratio 3,49
P/S Ratio 3,51 PEG Ratio 0,00
EV/EBITDA 11,18 Dividend Yield 0,00%
Market Cap 18,03B Enterprise Value 15,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,14B 4,24B 3,70B 3,39B 2,99B
Net Income 1,29B 32,62M 597,60M 340,66M 948,58M
EPS (Diluted) 6,41 0,15 2,65 1,52 4,27
Gross Profit 4,70B 3,86B 3,38B 3,14B 2,80B
Operating Income 1,34B 80,14M 651,77M 599,56M 637,54M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,96B 5,44B 6,78B 5,84B 4,93B
Total Liabilities 1,80B 2,00B 1,59B 1,47B 1,16B
Shareholders' Equity 5,17B 3,45B 5,19B 4,37B 3,77B
Total Debt 69,43M 43,54M 38,29M 41,46M 44,82M
Cash & Equivalents 3,10B 1,69B 3,21B 2,95B 2,06B
Current Assets 5,02B 3,24B 4,65B 4,09B 3,12B
Current Liabilities 1,52B 1,64B 1,24B 1,16B 854,31M

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#900 of 1052
26
Custom Capital Light Compounder
#148 of 218
32
Growth Growth Investing (Philip Fisher)
#123 of 157
39
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#171 of 332
50
Value Value Investing (Warren Buffett)
#78 of 203
46
Custom Balanced Risk
#146 of 151
25
Custom Lower Risk
#117 of 140
35

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026